Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (NABOGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03294395
Recruitment Status : Recruiting
First Posted : September 27, 2017
Last Update Posted : July 5, 2019
Sponsor:
Collaborator:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Information provided by (Responsible Party):
Henry J.C. de Vries, Public Health Service of Amsterdam

Brief Summary:

This study evaluates the efficacy of three experimental antibiotics in the treatment of uncomplicated anogenital gonorrhoea. Participants will be randomized to one of four study arms and will receive either one of the three experimental antibiotics (ertapenem, fosfomycin and gentamicin) or the current standard antibiotic (ceftriaxone). Both the study team and the participant are blinded to the administered treatment. This enables the investigators to compare the eradication capacity and safety of the experimental antibiotics with the standard treatment.

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.


Condition or disease Intervention/treatment Phase
Gonorrhea Drug: Ertapenem 1000 MG Drug: Fosfomycin Oral Suspension Drug: Gentamicin Sulfate, Injectable Drug: Ceftriaxone Phase 3

Detailed Description:

Antimicrobial resistance (AMR) to extended spectrum cephalosporins (ESC) among Neisseria gonorrhoeae (Ng) is a major public health concern. With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. This project aims to identify new treatment modalities for uncomplicated gonorrhoea using the registered drugs ertapenem, fosfomycin and gentamicin. This trial is a double blind randomized clinical non-inferiority trial with four treatment arms. 108 participants are randomly assigned to each study arm . Participants will receive either ceftriaxone 500mg intramuscularly (IM) or ertapenem 1000mg IM or gentamicin 5mg/kg IM with a maximum of 400mg (in two doses) supplemented with an oral placebo, or receive fosfomycin 6g oral suspension supplemented with an intramuscular placebo. The bacterial eradication capacity of the study antimicrobials at the included infection site is measured 7-14 days after treatment, using an RNA-based Nucleic Acid Amplification Test (NAAT).

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 346 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

A double-blind randomized clinical trial with non-inferiority design

*since October 2018 one study arm (fosfomycin) has been dropped. In a subset of these participants the plasma concentration of ceftriaxone, ertapenem and gentamicin is measured.

An open-label randomized substudy evaluating the pharmacokinetics of ceftriaxone ertapenem and fosfomycin in 60 healthy volunteers (this number is in addition to the 346 NABOGO participants with gonorrhea)

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: All participants receive either intramuscular treatment and if applicable intramuscular placebo. Both particpant and care provider are blind to the regimen.
Primary Purpose: Treatment
Official Title: New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial
Actual Study Start Date : September 18, 2017
Estimated Primary Completion Date : February 18, 2020
Estimated Study Completion Date : December 18, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Ceftriaxone im
Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
Drug: Ceftriaxone
single dose 500mg intramuscular injection
Other Name: no other names

Experimental: Ertapenem im
Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
Drug: Ertapenem 1000 MG
single dose 1000mg intramuscular injection
Other Name: Invanz

Experimental: Fosfomycin po
Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
Drug: Fosfomycin Oral Suspension
single dose 6g oral suspension
Other Name: Monuril

Experimental: Gentamicin im
Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
Drug: Gentamicin Sulfate, Injectable
single dose 5mg/kg (maximum 400mg) intramuscular injection
Other Name: no other names




Primary Outcome Measures :
  1. Proportion of participants with treatment success in each study arm for the included anatomic infection [ Time Frame: 7-14 days after treatment ]
    Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-14 days after treatment.


Secondary Outcome Measures :
  1. Proportion of participants with treatment success in each study arm at all anatomical infection sites [ Time Frame: 7-28 days after treatment ]
    Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-28 days after treatment.

  2. Incidence of treatment-emergent adverse events [ Time Frame: until 30 days after treatment ]
    The incidence, type and severity of treatment-related adverse events as assessed by CTCAE v4.0 will be measured.

  3. Antimicrobial susceptibility of Ng-strains to study antibiotics [ Time Frame: Day 0 (before treatment) - 28 (after treatment) ]
    The in vitro antimicrobial susceptibility (in MIC) of the experimental and reference treatment will be measured in all Ng strains collected at all infected anatomical sites of each participant at inclusion and in case of a positive test of cure.

  4. Blood plasma concentration of ceftriaxone, ertapenem and gentamicin in a subset of 60 NABOGO participants [ Time Frame: within 24 hours after treatment administration ]
    The blood plasma concentration will be measured 1 times within the first 24 hours after treatment administration. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and gentamicin.

  5. Duration of symptoms after treatment [ Time Frame: 1-30 days after treatment ]
    All participants are asked to report their symptoms daily in a diary, this will be evaluated at the follow-up visit (7-14 days after treatment) and at the online evaluation questionnaire (30 days after treatment). The mean duration of all symptoms after treatment will be measured for all study antibiotics.

  6. Clinical and demographic predictors for treatment failure [ Time Frame: until 7-14 days after treatment ]
    The investigators will measure if demographic (e.g. gender, HIV status) and clinical factors (e.g. anatomical location, duration of symptoms before treatment) are associated with treatment failure (treatment failure is defined as any case in which the participant received escape medication).

  7. Blood plasma concentration of ceftriaxone, ertapenem and fosfomycin in 60 healthy volunteers [ Time Frame: 24 hours ]
    Healthy volunteers will be randomly assigned to one of the three antibiotics. After administration of the antibiotic, the blood plasma concentration will be measured 4 times within the first 24 hours. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and fosfomycin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria main study

  • 18 years or older
  • Anorectal, cervical/vaginal or urethral Ng infection, diagnosed by the following:

    • Ng-positive Gram-stained smear (intracellular Gram-negative diplococci and leukocytes) and/or
    • Positive for Ng by nucleic acid amplification test (NAAT) (Aptima Combo 2) and/or
    • Positive for Ng by culture
  • Provide samples from the included infection site for NAAT and direct culture immediately before treatment
  • Willing to abstain from anal, vaginal and oral sex until the test of cure (TOC)-visit, or use condoms during sex
  • Willing and able to return for a TOC-visit 7-14 days after treatment
  • Provide informed consent
  • Accept intramuscular injections

Exclusion criteria main study

Pre-randomisation:

  • Suspicion of a complicated Ng infection based on signs and/or symptoms indicating pelvic inflammatory disease (PID), epididymitis, prostatitis or gonococcal arthritis*
  • Another (sexually transmitted) infection or a suspicion of another infection for which systemic antimicrobial therapy is indicated
  • Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
  • Not able to read/understand Dutch or English
  • HIV infection if:

    • Newly diagnosed HIV infection (upon the inclusion visit) and/or
    • CD4+ cell-count <200 cells/μL (as reported by the patient)
  • Known allergy or adverse reactions to ceftriaxone, ertapenemor gentamicin
  • Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
  • Known liver cirrhosis (based on history)
  • Known congestive heart failure (based on history)
  • Known myasthenia gravis
  • Known hearing loss or balance disorder, confirmed by an ear-nose-throat (ENT)-doctor or for which an ENT doctor has been consulted and a diagnostic process is still in progress (based on history)
  • Concurrent use of any of the following medication:

    • systemic antibacterial antimicrobials other than nitrofurantoin or metronidazole
    • systemic immunosuppressive drugs
    • systemic valproic acid
  • Use of any antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
  • Previous enrollment in the study
  • Concurrent participation in other non-observational medical research*
  • Unlikely to adhere to the study protocol

Post-randomisation:

Exclusion of participants from the modified intention to treat analysis (mITT):

  • Negative result of Ng NAAT of sample collected on T0 (the day of treatment). This could be the case in the following situations:

    1. Negative NAAT in spite of positive gram stain.
    2. Positive NAAT on pre-study visit but spontaneous clearance of the infection in the time period between first test and return visit for treatment (=study inclusion visit). A novel sample for NAAT will be collected on the study inclusion visit just before administration of treatment; if these results are Ng-negative a participant will be excluded of mITT.
  • Loss to follow-up, i.e. no study visit TOC 7-14 days after treatment administration.

Exclusion from per protocol analysis (PP):

  • Exclusion of mITT
  • Use of non-study related antibiotics after inclusion and prior to TOC visit
  • Condomless sexual contact with the primary anatomical gonorrhea site involved after inclusion and prior to TOC visit
  • Other protocol violations

Inclusion criteria PK substudy (healthy volunteers):

  • 18 years or older
  • Provide informed consent

Exclusion criteria PK substudy (healthy volunteers)

Pre-randomisation:

  • Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
  • Not able to read/understand Dutch or English
  • Known allergy or adverse reactions to ceftriaxone, ertapenem, or fosfomycin.
  • Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
  • Known liver cirrhosis (based on history)
  • Concurrent use of any of the following medication:

    • systemic valproic acid
    • systemic metoclopramide
  • Use of any systemic antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
  • Concurrent participation in other non-observational medical research (apart from NABOGO RCT)
  • Unlikely to adhere to the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03294395


Contacts
Layout table for location contacts
Contact: Myrthe M de Laat, MD 0031-20-5553960 mdlaat@ggd.amsterdam.nl
Contact: Henry JC de Vries, PhD, MD 0031-20-5555429 h.j.devries@amc.uva.nl

Locations
Layout table for location information
Netherlands
Public Health Service Recruiting
Amsterdam, Noord Holland, Netherlands, 1018WT
Contact: Myrthe M de Laat, MD    0031-20-555 3960    mdlaat@ggd.amsterdam.nl   
Contact: Henry JC de Vries, PhD, MD    0031-020-555 5429    h.j.devries@amc.nl   
Sponsors and Collaborators
Public Health Service of Amsterdam
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
Layout table for investigator information
Principal Investigator: Henry JC de Vries, PhD, MD Public Health Service of Amsterdam
  Study Documents (Full-Text)

Documents provided by Henry J.C. de Vries, Public Health Service of Amsterdam:
Layout table for additonal information
Responsible Party: Henry J.C. de Vries, Professor MD, PhD, Public Health Service of Amsterdam
ClinicalTrials.gov Identifier: NCT03294395    
Other Study ID Numbers: NABOGO
First Posted: September 27, 2017    Key Record Dates
Last Update Posted: July 5, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Henry J.C. de Vries, Public Health Service of Amsterdam:
Antimicrobial resistance
Antibiotics
Fosfomycin
Ertapenem
Gentamicin
Neisseria Gonorrhoeae
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonorrhea
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Sexually Transmitted Diseases
Infection
Genital Diseases, Male
Genital Diseases, Female
Gentamicins
Ceftriaxone
Ertapenem
Fosfomycin
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action